iifl-logo-icon 1

Shilpa Medicare Ltd Balance Sheet

799.4
(-4.28%)
Jan 21, 2025|03:31:20 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

8.68

8.68

8.68

8.15

Preference Capital

0

0

0

0

Reserves

2,134.04

2,108.9

2,056.99

1,629.68

Net Worth

2,142.72

2,117.58

2,065.67

1,637.83

Minority Interest

Debt

144.35

289.58

195.27

654.67

Deferred Tax Liability Net

107.76

104.68

144.92

94.17

Total Liabilities

2,394.83

2,511.84

2,405.86

2,386.67

Fixed Assets

814.57

835.36

858.89

1,123.24

Intangible Assets

Investments

246.45

243.92

237.5

219.32

Deferred Tax Asset Net

82.89

78.5

69.88

37.33

Networking Capital

1,247.8

1,349.23

1,223.75

891.53

Inventories

111.92

94.5

101.77

299.08

Inventory Days

131.47

Sundry Debtors

143.82

111.9

102.73

218.27

Debtor Days

95.94

Other Current Assets

1,098.7

1,228.15

1,579.39

542.22

Sundry Creditors

-58.41

-39.66

-38.55

-91.79

Creditor Days

40.35

Other Current Liabilities

-48.23

-45.66

-521.59

-76.25

Cash

3.13

4.83

15.83

115.27

Total Assets

2,394.84

2,511.84

2,405.85

2,386.69

Shilpa Medicare : related Articles

Shilpa Medicare Secures EU GMP Certification for Hyderabad Facility
23 Dec 2024|01:30 PM

The certification followed a successful inspection by the European Medicines Agency, Austria, held from September 24 to September 26 at the Nacharam, Hyderabad facility.

Read More
Shilpa Medicare’s JV Oncosol Gets FDA Nod for IMKELDI
28 Nov 2024|12:41 AM

This FDA approval is a milestone in cancer therapy as it presents a more convenient and precise alternative to the traditional tablet forms.

Read More
Shilpa Medicare Secures Phase III Trial Nod for Recombinant Albumin
26 Nov 2024|07:49 PM

  Shilpa Medicare is the first Indian company to gain approval for Phase III trials of Recombinant Human Albumin.

Read More
Shilpa Medicare Subsidiary Bags European Certification for Nifedipine
19 Nov 2024|05:28 PM

The European Directorate for the Quality of Medicines & Healthcare (EDQM) gave Shilpa Pharma Lifesciences, the company's subsidiary, the Certificate of Suitability (CEP) for Nifedipine.

Read More
Top 10 stocks for today - 4th October, 2024
4 Oct 2024|08:46 AM

Here are some of the stocks that may see significant price movement today: Avenue Supermarts, Bank of Baroda, HDFC Bank, etc.

Read More
Shilpa Medicare submits new drug application with USFDA
4 Sep 2024|08:59 PM

According to the firm, the NDA submission package is based on three clinical trials, many pre-clinical investigations.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.